In conclusion, our study suggests the influence of GSTM1 and GSTP1 polymorphisms on CML risk and treatment response, and also the interaction between GSTs polymorphisms and smoking plays a significant role on CML susceptibility. This evidence concerns the gene GSTM1 and chronic myelogenous leukemia, BCR-ABL1 positive.